print PRINT

SCIENCE > Health

Japanese drug maker to test regenerative therapy for COVID-19 treatment 

  • June 24, 2020
  • , Nikkei
  • JMH Summary

Nikkei front-paged an announcement made by Japanese pharmaceutical company Rohto yesterday that in August it plans to start clinical trials of regenerative therapy to treat coronavirus patients with severe cases of pneumonia. The Osaka-based drug manufacturer is aiming to verify the safety and effectiveness of a stem-cell-based treatment in which patients who have been put on ventilators due to pneumonia-like symptoms receive about 100 million mesenchymal stem cells per dose intravenously.  

  • Ambassador
  • Ukraine
  • COVID-19
  • Trending Japan